S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NYSE:MDT

Medtronic Stock Competitors

$130.02
-0.62 (-0.47 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$129.63
$131.31
50-Day Range
$122.75
$135.17
52-Week Range
$98.94
$135.89
Volume2.80 million shs
Average Volume4.35 million shs
Market Capitalization$174.73 billion
P/E Ratio45.46
Dividend Yield1.93%
Beta0.8

Medtronic (NYSE:MDT) Vs. ABT, ISRG, SYK, EW, BDX, and BSX

Should you be buying Medtronic stock or one of its competitors? The main competitors of Medtronic include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), and Boston Scientific (BSX). These companies are all part of the "health care equipment" industry.

Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.

Risk & Volatility

Abbott Laboratories has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

72.1% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 79.6% of Medtronic shares are owned by institutional investors. 1.5% of Abbott Laboratories shares are owned by insiders. Comparatively, 0.5% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Abbott Laboratories and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories15.85%26.75%12.31%
Medtronic12.29%13.85%7.49%

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.4%. Medtronic pays an annual dividend of $2.52 per share and has a dividend yield of 1.9%. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Abbott Laboratories has raised its dividend for 49 consecutive years and Medtronic has raised its dividend for 44 consecutive years.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Abbott Laboratories and Medtronic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories021102.85
Medtronic051612.82

Abbott Laboratories currently has a consensus target price of $129.4167, suggesting a potential upside of 4.06%. Medtronic has a consensus target price of $144.2381, suggesting a potential upside of 10.94%. Given Medtronic's higher possible upside, analysts clearly believe Medtronic is more favorable than Abbott Laboratories.

Valuation and Earnings

This table compares Abbott Laboratories and Medtronic's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$34.61 billion6.37$4.50 billion$3.6534.07
Medtronic$30.12 billion5.80$3.61 billionN/AN/A

Abbott Laboratories has higher revenue and earnings than Medtronic.

Summary

Abbott Laboratories beats Medtronic on 9 of the 17 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Insider and Institutional Ownership

79.6% of Medtronic shares are owned by institutional investors. Comparatively, 83.9% of Intuitive Surgical shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 0.8% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Medtronic has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Earnings & Valuation

This table compares Medtronic and Intuitive Surgical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$30.12 billion5.80$3.61 billionN/AN/A
Intuitive Surgical$4.36 billion28.48$1.06 billion$8.82118.29

Medtronic has higher revenue and earnings than Intuitive Surgical.

Profitability

This table compares Medtronic and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic12.29%13.85%7.49%
Intuitive Surgical31.43%16.18%14.23%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Medtronic and Intuitive Surgical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic051612.82
Intuitive Surgical09802.47

Medtronic currently has a consensus target price of $144.2381, suggesting a potential upside of 10.94%. Intuitive Surgical has a consensus target price of $952.8125, suggesting a potential downside of 8.68%. Given Medtronic's stronger consensus rating and higher possible upside, analysts clearly believe Medtronic is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats Medtronic on 8 of the 14 factors compared between the two stocks.

Stryker (NYSE:SYK) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Institutional and Insider Ownership

72.6% of Stryker shares are held by institutional investors. Comparatively, 79.6% of Medtronic shares are held by institutional investors. 6.7% of Stryker shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Stryker and Medtronic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker171402.59
Medtronic051612.82

Stryker currently has a consensus price target of $286.4286, indicating a potential upside of 3.54%. Medtronic has a consensus price target of $144.2381, indicating a potential upside of 10.94%. Given Medtronic's stronger consensus rating and higher possible upside, analysts plainly believe Medtronic is more favorable than Stryker.

Volatility & Risk

Stryker has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Valuation and Earnings

This table compares Stryker and Medtronic's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.35 billion7.27$1.60 billion$7.4337.23
Medtronic$30.12 billion5.80$3.61 billionN/AN/A

Medtronic has higher revenue and earnings than Stryker.

Profitability

This table compares Stryker and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker12.82%26.08%10.41%
Medtronic12.29%13.85%7.49%

Dividends

Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 0.9%. Medtronic pays an annual dividend of $2.52 per share and has a dividend yield of 1.9%. Stryker pays out 33.9% of its earnings in the form of a dividend. Stryker has raised its dividend for 1 consecutive years and Medtronic has raised its dividend for 44 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Medtronic beats Stryker on 10 of the 17 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Earnings & Valuation

This table compares Medtronic and Edwards Lifesciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$30.12 billion5.80$3.61 billionN/AN/A
Edwards Lifesciences$4.39 billion17.06$823.40 million$1.8664.55

Medtronic has higher revenue and earnings than Edwards Lifesciences.

Risk and Volatility

Medtronic has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Medtronic and Edwards Lifesciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic051612.82
Edwards Lifesciences061202.67

Medtronic currently has a consensus target price of $144.2381, indicating a potential upside of 10.94%. Edwards Lifesciences has a consensus target price of $118.4375, indicating a potential downside of 1.36%. Given Medtronic's stronger consensus rating and higher possible upside, research analysts clearly believe Medtronic is more favorable than Edwards Lifesciences.

Institutional and Insider Ownership

79.6% of Medtronic shares are owned by institutional investors. Comparatively, 80.1% of Edwards Lifesciences shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 1.4% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Medtronic and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic12.29%13.85%7.49%
Edwards Lifesciences29.69%29.73%19.10%

Summary

Edwards Lifesciences beats Medtronic on 8 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Profitability

This table compares Medtronic and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic12.29%13.85%7.49%
Becton, Dickinson and9.72%16.26%7.26%

Analyst Ratings

This is a summary of recent ratings for Medtronic and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic051612.82
Becton, Dickinson and05402.44

Medtronic currently has a consensus target price of $144.2381, suggesting a potential upside of 10.94%. Becton, Dickinson and has a consensus target price of $273.6250, suggesting a potential upside of 8.08%. Given Medtronic's stronger consensus rating and higher possible upside, equities research analysts clearly believe Medtronic is more favorable than Becton, Dickinson and.

Institutional & Insider Ownership

79.6% of Medtronic shares are held by institutional investors. Comparatively, 84.3% of Becton, Dickinson and shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 0.8% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Medtronic and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$30.12 billion5.80$3.61 billionN/AN/A
Becton, Dickinson and$17.12 billion4.25$874 million$10.2024.82

Medtronic has higher revenue and earnings than Becton, Dickinson and.

Dividends

Medtronic pays an annual dividend of $2.52 per share and has a dividend yield of 1.9%. Becton, Dickinson and pays an annual dividend of $3.32 per share and has a dividend yield of 1.3%. Becton, Dickinson and pays out 32.5% of its earnings in the form of a dividend. Medtronic has increased its dividend for 44 consecutive years and Becton, Dickinson and has increased its dividend for 50 consecutive years.

Volatility and Risk

Medtronic has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Summary

Medtronic beats Becton, Dickinson and on 13 of the 17 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Boston Scientific and Medtronic's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$9.91 billion6.42$-82,000,000.00$0.9646.56
Medtronic$30.12 billion5.80$3.61 billionN/AN/A

Medtronic has higher revenue and earnings than Boston Scientific.

Profitability

This table compares Boston Scientific and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Scientific4.56%12.67%6.41%
Medtronic12.29%13.85%7.49%

Risk and Volatility

Boston Scientific has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Boston Scientific and Medtronic, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Scientific021012.92
Medtronic051612.82

Boston Scientific currently has a consensus price target of $49.1338, suggesting a potential upside of 9.92%. Medtronic has a consensus price target of $144.2381, suggesting a potential upside of 10.94%. Given Medtronic's higher probable upside, analysts plainly believe Medtronic is more favorable than Boston Scientific.

Insider and Institutional Ownership

89.8% of Boston Scientific shares are held by institutional investors. Comparatively, 79.6% of Medtronic shares are held by institutional investors. 0.7% of Boston Scientific shares are held by insiders. Comparatively, 0.5% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Medtronic beats Boston Scientific on 7 of the 13 factors compared between the two stocks.


Medtronic Competitors List

Competitor NameBTM RankShare PriceAnalysts' Price TargetMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.9$124.37
-0.7%
$129.42
-4.1%
$220.49 billion$34.61 billion35.03109,000
Intuitive Surgical logo
ISRG
Intuitive Surgical
2.1$1,043.33
-0.1%
$952.81
-8.7%
$124.15 billion$4.36 billion77.988,081Analyst Downgrade
Stryker logo
SYK
Stryker
2.4$276.64
-0.2%
$286.43
-3.5%
$104.32 billion$14.35 billion50.6743,000
Edwards Lifesciences logo
EW
Edwards Lifesciences
2.2$120.07
-0.8%
$118.44
-1.4%
$74.84 billion$4.39 billion51.5314,900
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.4$253.18
-0.3%
$273.63
-8.1%
$72.71 billion$17.12 billion39.7565,000
Boston Scientific logo
BSX
Boston Scientific
2.1$44.70
-0.7%
$49.13
-9.9%
$63.65 billion$9.91 billion135.462,020Analyst Report
Analyst Revision
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
2.0$679.64
-0.4%
$675.00
-0.7%
$57.82 billion$2.71 billion81.019,300Short Interest ↑
DexCom logo
DXCM
DexCom
2.4$560.74
-2.1%
$507.47
-9.5%
$54.25 billion$1.93 billion106.815,500Insider Selling
ResMed logo
RMD
ResMed
2.1$279.48
-1.2%
$241.50
-13.6%
$40.71 billion$3.20 billion86.267,770
Baxter International logo
BAX
Baxter International
2.9$80.85
-0.1%
$91.18
-12.8%
$40.42 billion$11.67 billion36.922,020Analyst Report
STERIS logo
STE
STERIS
2.7$220.21
-0.1%
$242.40
-10.1%
$21.97 billion$3.11 billion65.9313,000
Insulet logo
PODD
Insulet
2.1$289.20
-0.5%
$283.50
-2.0%
$19.92 billion$904.40 million-628.701,900News Coverage
Hologic logo
HOLX
Hologic
2.5$76.48
-1.1%
$86.93
-13.7%
$19.39 billion$3.78 billion9.815,814
Teleflex logo
TFX
Teleflex
2.6$388.09
-0.3%
$455.80
-17.4%
$18.16 billion$2.54 billion52.3714,000
Abiomed logo
ABMD
Abiomed
2.0$350.36
-0.1%
$363.75
-3.8%
$15.90 billion$847.52 million104.271,725
Masimo logo
MASI
Masimo
1.9$283.55
-0.4%
$292.75
-3.2%
$15.61 billion$1.14 billion73.465,300
Hill-Rom logo
HRC
Hill-Rom
2.1$150.00
-0.2%
$137.67
-8.2%
$9.87 billion$2.88 billion42.2510,000Short Interest ↓
Globus Medical logo
GMED
Globus Medical
2.3$81.22
-0.3%
$82.18
-1.2%
$8.19 billion$789.04 million45.122,200
Integra LifeSciences logo
IART
Integra LifeSciences
1.6$72.18
-0.2%
$72.89
-1.0%
$6.10 billion$1.37 billion29.953,700
AtriCure logo
ATRC
AtriCure
2.1$71.75
-3.6%
$89.00
-24.0%
$3.29 billion$206.53 million-56.50750Gap Up
NuVasive logo
NUVA
NuVasive
1.5$63.16
-0.5%
$67.18
-6.4%
$3.26 billion$1.05 billion3,159.582,700
Integer logo
ITGR
Integer
2.2$91.16
-0.4%
$106.00
-16.3%
$3.01 billion$1.07 billion31.117,500
Alphatec logo
ATEC
Alphatec
2.4$13.74
-2.9%
$19.79
-44.0%
$1.38 billion$144.86 million-11.08296News Coverage
Cardiovascular Systems logo
CSII
Cardiovascular Systems
2.0$33.34
-1.6%
$44.75
-34.2%
$1.34 billion$258.97 million-98.06779Analyst Report
Analyst Revision
News Coverage
AngioDynamics logo
ANGO
AngioDynamics
2.0$24.19
-0.5%
$30.00
-24.0%
$929.96 million$291.01 million-29.50800Upcoming Earnings
News Coverage
CryoLife logo
CRY
CryoLife
2.2$23.22
-2.0%
$35.50
-52.9%
$912.69 million$253.23 million-74.901,200
Surmodics logo
SRDX
Surmodics
2.5$56.16
-0.7%
$73.00
-30.0%
$779.05 million$94.86 million561.66370
Orthofix Medical logo
OFIX
Orthofix Medical
1.7$38.91
-1.1%
$39.00
-0.2%
$766.33 million$406.56 million-92.641,036Gap Up
Accuray logo
ARAY
Accuray
1.9$3.89
-2.3%
N/A$353.33 million$396.29 million-55.57932News Coverage
Gap Down
Invacare logo
IVC
Invacare
2.0$5.17
-3.7%
$9.50
-83.8%
$180.99 million$850.69 million-4.793,400
Rockwell Medical logo
RMTI
Rockwell Medical
1.7$0.65
-3.1%
$5.00
-665.7%
$61.31 million$62.20 million-1.81300News Coverage
Gap Down
This page was last updated on 9/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.